http://www.blogtalkradio.com/aquarianradio/2017/12/29/ira-s-…et-theresa
Category: bioengineering – Page 189
Scientists, who had previously cloned polo ponies, have achieved yet another breakthrough in their work that could lead to the creation of genetically engineered “super-horses” that are faster, stronger and better jumpers than regular horses within two years.
Scientists in Argentina reportedly managed to rewrite the genomes of cloned horses by using a powerful DNA editing technique called CRISPR. They also produced healthy embryos that are now expected to be implanted into a surrogate mother by 2019.
CRISPR, an acronym that stands for Clustered, Regularly Interspaced, Short Palindromic Repeats, is basically a technique in a bacteria’s immune system. When a virus invades a bacterial cell, the CRISPR system captures a piece of the virus’s DNA and slides it into a section of the bacteria’s own DNA, allowing it to detect and destroy the virus as well as similar viruses in future attacks.
Read more
Usually, when we’ve referred to Crispr, we’ve really meant Crispr/Cas9—a riboprotein complex composed of a short strand of RNA and an efficient DNA-cutting enzyme. It did for biology and medicine what the Model T did for manufacturing and transportation; democratizing access to a revolutionary technology and disrupting the status quo in the process. Crispr has already been used to treat cancer in humans, and it could be in clinical trials to cure genetic diseases like sickle cell anemia and beta thalassemia as soon as next year.
But like the Model T, Crispr Classic is somewhat clunky, unreliable, and a bit dangerous. It can’t bind to just any place in the genome. It sometimes cuts in the wrong places. And it has no off-switch. If the Model T was prone to overheating, Crispr Classic is prone to overeating.
Even with these limitations, Crispr Classic will continue to be a workhorse for science in 2018 and beyond. But this year, newer, flashier gene editing tools began rolling off the production line, promising to outshine their first-generation cousin. So if you were just getting your head around Crispr, buckle up. Because gene-editing 2.0 is here.
Read more
The US federal government has lifted an enforced moratorium on funding research into how to make viruses deadlier and more transmissible.
The moratorium, which was imposed three years ago, froze funding for what’s called “gain of function” research: controversial experiments seeking to alter pathogens and make them even more dangerous. Now, the money is back on the table, giving those trials the green light once more.
The director of the National Institutes of Health (NIH), Francis S. Collins, announced the lifting of the moratorium on Tuesday, saying gain of function (GOF) research with viruses like influenza, MERS, and SARS could help us “identify, understand, and develop strategies and effective countermeasures against rapidly evolving pathogens that pose a threat to public health”.
Read more
Brendan John Frey FRSC (born 29 August 1968) is a Canadian-born machine learning and genome biology researcher, known mainly for his work on factor graphs, the wake-sleep algorithm for deep learning, and using machine learning to model genome biology and understand genetic disorders. He founded Deep Genomics and is currently its CEO, and he is a Professor of Engineering and Medicine at the University of Toronto. He co-developed a new computational approach to identifying the genetic determinants of disease, was one of the first researchers to successfully train a deep neural network, and was a pioneer in the introduction of iterative message-passing algorithms.
Frey studied computer engineering and physics at the University of Calgary (BSc 1990) and the University of Manitoba (MSc 1993), and then studied neural networks and graphical models as a doctoral candidate at the University of Toronto under the supervision of Geoffrey Hinton (PhD 1997). He was an invited participant of the Machine Learning program at the Isaac Newton Institute for Mathematical Sciences in Cambridge, UK (1997) and was a Beckman Fellow at the University of Illinois at Urbana Champaign (1999).
Following his undergraduate studies, Frey worked as a Junior Research Scientist at Bell-Northern Research from 1990 to 1991. After completing his postdoctoral studies at the University of Illinois at Urbana-Champaign, Frey was an Assistant Professor in the Department of Computer Science at the University of Waterloo, from 1999 to 2001.
In 2001, Frey joined the Department of Electrical and Computer Engineering at the University of Toronto and was cross-appointed to the Department of Computer Science, the Banting and Best Department of Medical Research and the Terrence Donnelly Centre for Cellular and Biomolecular Research. From 2008 to 2009, he was a Visiting Researcher at Microsoft Research, Cambridge, UK, and a Visiting Professor in the Cavendish Laboratories and Darwin College at Cambridge University. Between 2001 and 2014, Frey consulted for several groups at Microsoft Research and acted as a member of its Technical Advisory Board.
In 2014, Frey co-founded Deep Genomics, a Toronto company that develops machine learning methods to model the deep biological architectures that relate genetic mutations to disease. The company’s goal is to bridge the genotype-phenotype gap, which is a pain point in genetic testing, pharmaceuticals, personalized medicine and health insurance.
——-